Oncology: Clinical Therapy and Diagnosis -> Clinical Diagnosis -> GU 587

587 - 68Ga-PSMA-11 PET/CT detects prostate cancer at early biochemical recurrence with superior detection rate and reader agreement when compared to 18F-Fluciclovine PET/CT in a prospective head-to-head comparative phase 3 study< (ID 1281)

Session Name
69 - Prostate Diagnosis I
Speakers
Authors
Presentation Topic
Oncology: Clinical Therapy and Diagnosis -> Clinical Diagnosis -> GU
Presentation Number
587

Previous Eposter
557 - FES mean standardized uptake value is a prognostic marker for patients with endometrial carcinoma (ID 759)

Next Eposters
601 - Dedicated Breast PET for Detection of Early Treatment Response in Breast Cancer Patients (ID 560)
615 - Value of 18F-FDG PET CT in the initial staging, interim therapeutic and prognostic evaluation of marginal zone lymphoma (ID 578)
619 - Automated PET/CT radiomic analysis with machine learning for identifying bone marrow involvement in the patients with suspected relapsed acute leukemia (ID 583)
639 - Analysis of [11C]Choline Using High Pressure Ion Chromatography System (HPIC) with Autosampler (ID 370)
643 - Image-based biomarkers for bone sarcomas using F-18 FDG PET/CT: determination of optimal parameters and their prognostic threshold (ID 625)
1000 - Targeting of PD-L1 in mouse xenograft tumors by 89Zr-atezolizumab is specific but strongly mass-dependent (ID 52)
1001 - Immuno-PET imaging of 89Zr labeled novel anti-ED-B domain antibody (ID 53)
1002 - Deglycosylated CD8-specific immunoPET probe prevents antibody-mediated depletion of CD8+ immune cells (ID 54)
1003 - Evaluation of binding specificity of target-specific radioligands in xenografts by multi-modal PET and MR imaging using the Hen’s egg test chorioallantoic membrane (HET-CAM) model (ID 55)
1006 - Immuno-PET Imaging of the VEGFR-2 Expression in Prostate Cancer Using 89Zr-labeled Ramucirumab (ID 58)